Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1864-1872

  Halvorsen, Sigrun ^a   Atar, Dan ^a,b   Yang, Hongqiu ^c   De Caterina, Raffaele ^d   Erol, Cetin ^e   Garcia, David ^f   Granger, Christopher B ^c   Hanna, Michael ^g   Held, Claes ^h   Husted, Steen ⁱ   Hylek, Elaine M ^j   Jansky, Petr ^k   Lopes, Renato D ^c   Ruzyllo, Witold ^l   Thomas, Laine ^c   Wallentin, Lars ^h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

^e ANKARA UNIVERSITY   (Turkey)

^f UNIVERSITY OF WASHINGTON   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^j BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^l INSTITUTE OF CARDIOLOGY   (Poland)

more..

Author keywords

Age; Anticoagulants; Apixaban; Atrial fibrillation; Bleeding; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTACID AGENT; ANTILIPEMIC AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASSOCIATION; BODY WEIGHT; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGE; ANALYSIS OF VARIANCE; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; EMBOLISM; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RISK FACTOR; STROKE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84904047925     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu046     Document Type: Article

References (20)

1. Heeringa J, Van Der Kuip DA, Hofman A, Kors JA, Van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006;27:949-953
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-272
4. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867
5. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-2696
6. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010;138:1093-1100
7. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005;46:1729-1736
8. Steffel J, Braunwald E. Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011;32:1968-1976
9. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. J Am Coll Cardiol 2012;59:1413-1425
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992
11. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010;159:331-339
12. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E. BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007;370:493-503
13. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser S, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-2747
14. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-2830
15. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander J, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the ARISTOTLE trial. Am Heart J 2013;166: 549-558
16. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166-2176
17. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, MunawarM, O-Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817
18. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-Term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372
19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891
20. Vanwalraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE. Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators. Stroke 2009;40:1410-1416.